BBO-10203

BBO-10203 is a potent inhibitor of PI3Kα and KRAS G12C, selectively and covalently binding to Cys242 in the RAS-Binding Domain of PI3Kα, and inhibiting both the GTP-bound and GDP-bound states of KRAS G12C with an IC50 of 0.031 nM and an EC50 of 0.02 nM. BBO-10203 disrupts the interaction between RAS isoforms and PI3Kα, leading to the inhibition of RAS-mediated PI3Kα activation, and reduces pERK expression, cell growth, and induces G1 arrest and apoptosis. BBO-10203 can be used for the research of breast cancer, colorectal cancer, and non-small cell lung cancer .


Cat. No.: EX-A12048	Purity: >98%

	Chemical structure of BBO-10203

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
1mg	400	In-stock
5mg	830	In-stock
10mg	1150	In-stock
25mg	1960	In-stock
50mg	2880	In-stock
100mg	4600	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	2971769-60-3
Purity	>98%
Formula	C34H30F2N6O3S
Mol Weight	640.702
Color	White to off-white
State	Solid
Solubility	Soluble in DMSO
Shelf Life	>3 years if stored properly
Storage	Powder 4℃,protect from light, 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Fan Z, et al. Precise regulation of RAS-Mediated PI3Kα activation: therapeutic potential of BBO-10203 in cancer treatment. Exp Hematol Oncol. 2025;14(1):115. Published 2025 Sep 29. [2]. Kerstin W. Sinkevicius, et al. Abstract C082: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia. Mol Cancer Ther (2025) 24 (10_Supplement): C082.
CoA	CoA of BBO-10203

Smiles:	O=C(C=C)N1CCN2N=C(C=C2C1C)C=3N=C(C=4C=CC5=C(C=NN5C)C4)C=6C=CSC6C3C7=C(F)C=C(F)C=C7OCCOC


		Search